LNC Biotech

LNC Biotech is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of targeted radiopharmaceuticals for oncology. The company utilizes a theranostic approach, integrating molecular imaging with targeted radionuclide therapy to provide precision treatment for solid tumors. Its proprietary technology platform focuses on high-affinity ligands targeting biomarkers such as Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA). In November 2021, LNC Biotech was acquired by Grand Pharmaceutical Group (Grand Pharma), becoming a central pillar of the group's radiopharmaceutical R&D strategy. The company's lead candidates, including LNC-1003 and LNC-1004, are currently undergoing clinical trials for various cancers. LNC Biotech maintains strategic partnerships with global isotope suppliers like ITM to ensure the scalability and reach of its therapeutic pipeline.